Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Niagen Bioscience (NAGE) over the last 15 years, with Q3 2025 value amounting to $79.8 million.

  • Niagen Bioscience's Shares Outstanding (Weighted Average) rose 501.11% to $79.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.8 million, marking a year-over-year increase of 501.11%. This contributed to the annual value of $75.9 million for FY2024, which is 125.89% up from last year.
  • Latest data reveals that Niagen Bioscience reported Shares Outstanding (Weighted Average) of $79.8 million as of Q3 2025, which was up 501.11% from $79.2 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Shares Outstanding (Weighted Average) high stood at $79.8 million for Q3 2025, and its period low was $64.2 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $75.0 million (2023), whereas its average is $72.7 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first soared by 1162.45% in 2021, then rose by 15.97% in 2022.
  • Niagen Bioscience's Shares Outstanding (Weighted Average) (Quarter) stood at $67.2 million in 2021, then grew by 3.79% to $69.7 million in 2022, then increased by 7.54% to $75.0 million in 2023, then grew by 1.26% to $75.9 million in 2024, then increased by 5.07% to $79.8 million in 2025.
  • Its last three reported values are $79.8 million in Q3 2025, $79.2 million for Q2 2025, and $77.8 million during Q1 2025.